GSK Partners With Santaris On RNA Antagonists For Viral Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
$700 million deal gives GlaxoSmithKline options on up to four different viral disease programs; deal marks Santaris’ expansion into virology, chief exec McCullah tells “The Pink Sheet” DAILY.
You may also be interested in...
MicroRNA Momentum Builds, But Will Big Pharma Embrace It?
While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.
Wyeth And Santaris To Collaborate On RNA Antagonists
Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.
Wyeth And Santaris To Collaborate On RNA Antagonists
Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.